AgeX Therapeutics (NYSE:AGE) Sees Unusually-High Trading Volume

Shares of AgeX Therapeutics, Inc. (NYSE:AGEGet Free Report) saw strong trading volume on Monday . 11,537 shares changed hands during mid-day trading, an increase of 286% from the previous session’s volume of 2,991 shares.The stock last traded at $16.88 and had previously closed at $22.32.

AgeX Therapeutics Stock Down 10.5 %

The company has a market cap of $14.05 million, a P/E ratio of -1.00 and a beta of 1.18. The business has a fifty day moving average of $1.39 and a 200 day moving average of $0.71.

Hedge Funds Weigh In On AgeX Therapeutics

An institutional investor recently raised its position in AgeX Therapeutics stock. Creative Planning boosted its position in AgeX Therapeutics, Inc. (NYSE:AGEFree Report) by 38.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 72,360 shares of the company’s stock after purchasing an additional 20,000 shares during the quarter. Creative Planning owned approximately 0.19% of AgeX Therapeutics worth $42,000 at the end of the most recent quarter. 12.50% of the stock is currently owned by institutional investors and hedge funds.

AgeX Therapeutics Company Profile

(Get Free Report)

AgeX Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease.

Featured Articles

Receive News & Ratings for AgeX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AgeX Therapeutics and related companies with's FREE daily email newsletter.